Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Thomas Kaley, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, Los Angeles
Los Angeles, California, United States
- University of California San Francisco
San Francisco, California, United States
- University of Miami
Miami, Florida, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack
Commack, New York, United States
- Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Memorial Sloan Kettering Nassau
Uniondale, New York, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- University of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Jan 2016
- Primary completion
- 31 Jan 2027
- Completion
- 31 Jan 2027
- Last update posted
- 3 Mar 2026
- Registered enrollment
- 27
- Registry id
- NCT02658279
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.